Liver cancer working group report

Japanese Journal of Clinical Oncology

Volumn 40, Issue SUPPL. 1, 2010, Pages

  Kudo, Masatoshi ^a   Han, Kwang Hyub ^b   Kokudo, Norihiro ^c   Cheng, Ann Lii ^d   Choi, Byung Ihn ^e   Furuse, Junji ^f   Izumi, Namiki ^g   Park, Joong Won ^h   Poon, Ronnie T ⁱ   Sakamoto, Michiie ^j  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Yonsei University College of Medicine   (South Korea)

^c UNIVERSITY OF TOKYO   (Japan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e Seoul National University College of Medicine   (South Korea)

^f KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g MUSASHINO RED CROSS HOSPITAL   (Japan)

^h National Cancer Center   (South Korea)

ⁱ UNIVERSITY OF HONG KONG   (Hong Kong)

^j KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Diagnosis; Epidemiology; Etiology; Liver cancer; Treatment

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BRIVANIB; CEDIRANIB; CISPLATIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEFITINIB; LAPATINIB; LILIFANIB; PLACEBO; SORAFENIB; SUNITINIB; THALIDOMIDE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER SCREENING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; ULTRASOUND; ASIA; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS;

ASIA; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS;

EID: 77957268387     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq123     Document Type: Article

References (35)

1. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J. Cancer Incidence in Five Continents. France: IARC Scientific Publications 2010.
2. Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology 2010;53:39-43.
3. Han KH, Kim JK. Liver cancer in Korea. Hepatol Res 2007;37(Suppl. 2):S106-9.
4. Yu MC, Yuan JM, Govindarajan S, Ross RK. Epidemiology of hepatocellular carcinoma. Can J Gastroenterol 2000;14:703-9.
5. Ikai I, Arii S, Okazaki M, Okita K, Omata M, Kojiro M, et al. Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res 2007;37:676-91.
6. Kim SR, Kudo M, Hino O, Han KH, Chung YH, Lee HS. Epidemiology of hepatocellular carcinoma in Japan and Korea. A review. Oncology 2008;75(Suppl. 1):13-6.
7. Yuen MF, Hou JL, Chutaputti A. Hepatocellular carcinoma in the Asia Pacific region. J Gastroenterol Hepatol 2009;24:346-53.
8. NiYH,HuangLM,ChangMH,YenCJ,LuCY,YouSL,etal. Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies. Gastroenterology 2007;132: 1287-93.
9. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329-38.
10. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711.
11. Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg 2007;245:909-22.
12. Kudo M, Chung H, Haji S, Osaki Y, Oka H, Seki T, et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 2004;40:1396-405.
13. Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000;31:330-5.
14. Chan AC, Poon RT, Ng KK, Lo CM, Fan ST, Wong J. Changing paradigm in the management of hepatocellular carcinoma improves the survival benefit of early detection by screening. Ann Surg 2008;247:666-73.
15. Amarapurkar D, Han KH, Chan HL, Ueno Y. Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region. J Gastroenterol Hepatol 2009;24:955-61.
16. Makuuchi M, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawasaki S, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 2008;38:37-51.
17. Kudo M, Okanoue T. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology 2007;72:S2-15.
18. Hatanaka K, Kudo M, Minami Y, Ueda T, Tatsumi C, Kitai S, et al. Differential diagnosis of hepatic tumors: value of contrast-enhanced harmonic sonography using the newly developed contrast agent, Sonazoid. Intervirology 2008;51:S61-9.
19. Kudo M. The 2008 Okuda lecture: management of hepatocellular carcinoma: from surveillance to molecular targeted therapy. J Gastroenterol Hepatol 2010;25:439-52.
20. Tatsumi C, Kudo M, Ueshima K, Kitai S, Ishikawa E, Yada N, et al. Non-invasive evaluation of hepatic fibrosis for type C chronic hepatitis. Intervirology 2010;53:76-81.
21. Kojiro M, Wanless I, Alves V, Badve S, Balabaud C, Bedossa P, et al. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009;49:658-64.
22. Todo S, Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg 2004;240:451-9, discussion 9-61.
23. Practice guidelines for management of hepatocellular carcinoma 2009. Korean J Hepatol 2009;15:391-423.
24. Omata M, Lesmana L, Tateishi R, Chen P, Lin S, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010; Epub ahead of print.
25. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
26. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
27. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-300.
28. Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008;99:159-65.
29. Shim JH, Park JW, Choi JI, Park BJ, Kim CM. Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a hepatitis B virus-endemic area. J Cancer Res Clin Oncol 2009;135:617-25.
30. Yau T, Chan P, Ng KK, Chok SH, Cheung TT, Fan ST, et al. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 2009;115:428-36.
31. Arii S, Sata M, Sakamoto M, Shimada M, Kumada T, Shiina S, et al. Management of hepatocellular carcinoma: Report of consensus meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res 2010;40:667-85.
32. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008;48:1312-27.
33. Okita K, Imanaka K, Chiba N, Tak W, Nakachi K, Takayama T, et al. Phase III study of sorafenib in patients in Japan and Korea with advanced hepatocellular carcinoma (HCC) treated after transarterial chemoembolization. ASCO Gastrointestinal Cancers Symposium Proceedings 2010;89 (LBA128).
34. Park JW, Walters I, Raoul JL, Harris R, Cai C, Thomas M. Phase II open-label study of brivanib alaniante in patients with hepatocellular carcinoma. ILCA. 2008; abstract #O-013.
35. Raoul JL, Finn RS, Kang WK, Park JW, Harris R, Coric V, et al. Phase 2 study of firstand second-line treatment with brivanib in patients with hepatocellular carcinoma. ILCA. 2009; abstract #P-0111.